Ignite Creation Date:
2024-05-06 @ 4:55 PM
Last Modification Date:
2024-10-26 @ 2:18 PM
Study NCT ID:
NCT05132127
Status:
COMPLETED
Last Update Posted:
2023-10-03
First Post:
2021-11-11
Brief Title:
Sutimlimab BIVV009 for the Adult Participants With Cold Agglutinin Disease CAD Who Have Completed Phase 3 Studies CARDINAL or CADENZA in Japan
Sponsor:
Organization:
Sanofi
Study Design
Study Type:
INTERVENTIONAL
Expanded Access Type Individual:
None
Expanded Access Type Intermediate:
None
Expanded Access Type Treatment:
None
Patient Registry:
None
Target Duration:
None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention:
None
Bio Spec Description:
None
Enrollment Count:
7
Enrollment Type:
ACTUAL
Design Primary Purpose:
Design Masking:
Phases:
| Name |
|---|
| PHASE3 |
Observational Models:
Time Perspective List:
Who Masked List: